Supernus Pharmaceuticals IncNASDAQ:SUPN
- LAST PRICE36.2600
- TODAY'S CHANGE (%)0.1600 (0.4432%)
- Bid / Lots36.2200/ 1
- Ask / Lots36.2900/ 6
- Open / Previous Close36.1100 / 36.1000
- Day Range
- 52 Week Range
- Volume47,327
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SUPN |
|---|---|---|
| 09:32 ET | 2299 | 35.85 |
| 09:33 ET | 100 | 36.135 |
| 09:35 ET | 100 | 36.065 |
| 09:37 ET | 300 | 36.065 |
| 09:42 ET | 200 | 36.02 |
| 09:44 ET | 1129 | 35.9496 |
| 09:50 ET | 497 | 35.965 |
| 09:51 ET | 858 | 35.98 |
| 09:55 ET | 100 | 36.12 |
| 09:57 ET | 300 | 36.08 |
| 10:00 ET | 131 | 36.098 |
| 10:04 ET | 1597 | 36.22 |
| 10:06 ET | 200 | 36.235 |
| 10:11 ET | 100 | 36.275 |
| 10:13 ET | 400 | 36.21 |
| 10:15 ET | 404 | 36.2 |
| 10:18 ET | 375 | 36.02 |
| 10:20 ET | 200 | 35.95 |
| 10:22 ET | 100 | 35.99 |
| 10:38 ET | 100 | 35.98 |
| 10:45 ET | 100 | 36.015 |
| 10:47 ET | 500 | 36.05 |
| 11:00 ET | 100 | 36.16 |
| 11:05 ET | 1100 | 36.26 |
| 11:12 ET | 200 | 36.26 |
| 11:14 ET | 1007 | 36.18 |
| 11:16 ET | 906 | 36.215 |
| 11:18 ET | 100 | 36.19 |
| 11:20 ET | 400 | 36.23 |
| 11:21 ET | 235 | 36.26 |
| 11:41 ET | 350 | 36.29 |
| 11:45 ET | 100 | 36.26 |
| 11:48 ET | 200 | 36.21 |
| 11:59 ET | 1200 | 36.22 |
| 12:01 ET | 100 | 36.26 |
| 12:03 ET | 1192 | 36.205 |
| 12:12 ET | 100 | 36.22 |
| 12:14 ET | 200 | 36.19 |
| 12:15 ET | 762 | 36.18 |
| 12:19 ET | 1000 | 36.315 |
| 12:21 ET | 300 | 36.35 |
| 12:24 ET | 700 | 36.36 |
| 12:26 ET | 100 | 36.29 |
| 12:28 ET | 1081 | 36.29 |
| 12:39 ET | 300 | 36.26 |
| 12:42 ET | 702 | 36.245 |
| 12:51 ET | 100 | 36.18 |
| 12:55 ET | 300 | 36.26 |
| 12:57 ET | 100 | 36.26 |
Nov 13, 2024
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference, from 4:30PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:30PM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 4, 2024
Supernus Announces Third Quarter 2024 Financial Results, from 4:05PM ET on Monday Nov 04, 2024 by Dow Jones
4:05PM ET on Monday Nov 04, 2024 by Dow Jones*DJ Supernus Pharmaceuticals 3Q EPS 69c >SUPN, from 4:05PM ET on Monday Nov 04, 2024 by Dow Jones
4:05PM ET on Monday Nov 04, 2024 by Dow Jones
Oct 31, 2024
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024, from 4:10PM ET on Thursday Oct 31, 2024 by Dow Jones
4:10PM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Supernus Pharmaceuticals Inc | 2.0B | 33.9x | -59.02% |
Phibro Animal Health Corp | 961.6M | 55.2x | -46.35% |
Eagle Pharmaceuticals Inc | 12.3M | 0.9x | -4.75% |
Elite Pharmaceuticals Inc | 658.9M | -103.5x | --- |
Shengtai Pharmaceutical Inc | 10.0 | 0.0x | --- |
Medicine Man Technologies Inc | 6.2M | --- | --- |
Company Information
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.
Contact Information
- Headquarters
- 9715 Key West AvenueROCKVILLE, MD, United States 20850
- Phone
- 301-838-2500
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Charles Newhall
- President, Chief Executive Officer, Secretary, Director
- Jack Khattar
- Chief Financial Officer, Senior Vice President
- Timothy Dec
- Senior Vice President - Intellectual Property, Chief Scientific Officer
- Padmanabh Bhatt
- Senior Vice President - Quality, GMP Operations and Information Technology and Regulatory Affairs
- Frank Mottola
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.0B |
|---|---|
Revenue (TTM) | $652.0M |
Shares Outstanding | 55.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.90 |
EPS | $1.07 |
Book Value | $16.84 |
P/E Ratio | 33.9x |
Price/Sales (TTM) | 3.1 |
Price/Cash Flow (TTM) | 14.0x |
Operating Margin | 9.09% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
